The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

By the time her cancer was caught, six months after her symptoms began and two days after her 46th birthday, Louise Greenbank ...

This week in oncology has been marked by significant strides in targeted therapies, a re-evaluation of established treatment paradigms, and compelling evidence for the impact of lifestyle ...

A world-first blood cancer therapy called belantamab mafodotin (Blenrep) is now available on the NHS in England for multiple ...

Several cancers are becoming more common in young adults, including testicular cancer, melanoma, and cervical cancer. Blood-related cancers like B-cell lymphomas and plasma cell neoplasms are also on ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

By Daniella Parra A new study published in the British Journal of Haematology confirms that the SKY92 gene expression profiling test significantly enhances risk stratification in multiple myeloma ...

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...